The limitations of cancer cell lines have led to the development of direct patient-derived xenograft models. However, the interplay between the implanted human cancer cells and recruited mouse stromal and immune cells alters the tumor microenvironment and limits the value of these models. To overcome these constraints, we have developed a technique to expand human hematopoietic stem and progenitor cells (HSPCs) and use them to reconstitute the radiation-depleted bone marrow of a NOD/SCID/IL2rg − / − (NSG) mouse on which a patient's tumor is then transplanted (XactMice). The human HSPCs produce immune cells that home into the tumor and help replicate its natural microenvironment. Despite previous passage on nude mice, the expression of epithelial, stromal and immune genes in XactMice tumors aligns more closely to that of the patient tumor than to those grown in nonhumanized mice-an effect partially facilitated by human cytokines expressed by both the HSPC progeny and the tumor cells. The human immune and stromal cells produced in the XactMice can help recapitulate the microenvironment of an implanted xenograft, reverse the initial genetic drift seen after passage on non-humanized mice and provide a more accurate tumor model to guide patient treatment.
INTRODUCTION
The absence of native tumor stroma and interaction with the immune system are major limitations of xenograft models for studies of human tumor growth and metastasis. To produce a representative environment, xenograft tumor models must account for interactions between tumor, stromal, vascular and immune cells. 1, 2 Cell lines become homogeneous, and epithelialstromal interactions are no longer present in vitro, [3] [4] [5] consequently, conventional studies in cell line-derived tumors poorly predict clinical efficacy. 6 Patient-derived xenografts implanted into immunocompromised mice are more representative of patient tumor growth, although genetic drift is observed in microenvironment genes, [7] [8] [9] [10] perhaps because the tumor stroma consists of recruited mouse cells. 11 Recent studies have taken incremental steps toward overcoming this obstacle. It has been shown that human tumors implanted with their own stromal tissues can temporarily simulate aspects of the host tumor microenvironment in immunocompromised mice. 12 Alternatively, human hematopoietic cells can be engrafted in NOD/SCID/IL2rg − / − (NSG) mice to generate many features of the human immune system in these animals. 13 In vitro modification of hematopoietic progenitor cells can produce human leukemia and lymphoma models with accurate bone marrow tumor microenvironments, 14, 15 whereas the introduction of human T cells and experimental monoclonal antibodies can be used to test immunotherapies in NSG xenograft models. 16 Finally, the infiltration and activation of myeloid cells in xenografts has been examined in genetically modified NSG mice. 17 However, a comprehensive examination of the growth, tumor-stroma interaction and impact of humanization on gene expression of patient-derived xenograft in humanized mouse models has not been conducted.
We have developed an ex vivo technique to expand human hematopoietic stem and progenitor cells (HSPCs) derived from either cord blood or granulocyte colony-stimulating factor (G-CSF)-mobilized adult peripheral blood. 18 These HSPCs contain a population of rare hematopoietic stem cells capable of reconstituting the hematopoietic system of a mouse into which patient tumors are subsequently transplanted. In these humanized xenochimeric mice, or XactMice (Figure 1a) , the engrafted human HSPCs can express the chemical stimuli necessary to give rise to stromal and immune cells that recreate the original tumor microenvironment observed clinically. The promise of this model is that it can provide a tumor microenvironment more representative of the human host, and it can reverse, at least partially, the genetic drift observed in classical patient-derived xenograft models.
RESULTS

Expansion of human HSPCs enables the generation of cohorts of XactMice
The generation of cohorts of XactMice with HSPCs from the same donor requires the expansion of HSPCs. The expansion of HSPCs from donated cord blood, or from G-CSF-mobilized patient peripheral blood, was achieved using a protocol recently described by Bird et al, 18 which utilizes MYC and Bcl2 proteins fused with the HIV protein transduction peptide Tat. Used in combination, Tat-MYC and Tat-Bcl2 are capable of expanding HSPCs long term; however, these fusion proteins are degraded within 48 h after being taken up by the cells. Therefore, there is no trace of these activities when the expanded HSPCs are transplanted into mice. Under these conditions, HSPCs proliferate stably in vitro (Figure 1b ) while maintaining the hematopoietic stem cells-associated abilities of self-renewal and differentiation into B and T cells in immunocompromised mice. After expansion in culture, we injected the HSPCs into sublethally irradiated NSG mice to generate XactMice. We verified the HSPC-mediated bone marrow reconstitution by periodic flow cytometry of mouse peripheral blood for the presence of the hematopoietic cells expressing CD3 and CD45 human antigens (Figure 1c ). ) with the standard errors were used to create the recorded growth curves.
CD45
We examined the peripheral blood of a cohort of XactMice over 6 months and found that this human CD3/45+ cell population remains stable (Figure 1d ). In addition, after almost a year, we could still observe human T and B cells in the bone marrow and spleen ( Supplementary Figures 1a and b) , indicating that the progenitor cells continue to proliferate after engraftment.
We have established a xenograft tumor bank, consisting of tumors from head and neck squamous cell carcinoma patients undergoing surgical resection. 19 Freshly resected tumor tissue is implanted heterotopically and then passaged in the flanks of nude mice. Although the passaged heterotopic tumors initially retain the histological features of the original tumor (also shown in 20, 21 ), the human stroma is lost after 2-3 passages. We selected two cases from this tumor bank (CUHN004, passage 14; CUHN013, passage 5), and implanted them into cohorts of nude, NSG and XactMice. We observed no significant differences in the tumor growth rate or gross histology between the different mouse strains, with the NSG and XactMice having identical growth rates (Figures 1e and f; Supplementary Figure 1c) . To ensure reproducibility, experiments were repeated at least twice and all cohorts in this and subsequent experiments were composed of at least five randomly distributed male and female XactMice.
We also generated XactMice cohorts using expanded HSPCs from peripheral blood of adults treated with G-CSF, which results in an increase in peripheral blood HSPCs and creates a window for their acquisition by a peripheral blood draw. We implanted tumor cells into the flanks of these XactMice, along with nude and NSG controls. Subsequent analysis revealed that the engrafted HSPCs were present in the bone marrow of these XactMice, and their progeny could be seen in the spleen, peripheral blood and in the tumor (Supplementary Figure 2, upper two panels). Finally, we generated cohorts of XactMice from the HSPCs of head and neck squamous cell carcinoma patients undergoing induction chemotherapy that received G-CSF to hasten bone marrow recovery. 22 Analysis of the bone marrow, spleen and blood of these mice showed that the HSPCs successfully engrafted. As none of the patients from which these HSPCs were collected ultimately required surgery, no tissue existed to implant on these XactMice (Supplementary Figure 2 , lower panel). Although the ability to create XactMice from peripheral blood increases the utility of this model, the additional experiments shown below were conducted utilizing cord blood donors to minimize individual variations in the initial cohorts.
Human cells derived from humanized bone marrow are present in the stroma of XactMice tumors The stroma that forms in a developing tumor has two primary cellular origins: (1) mesenchymal and immune cells originating from the bone marrow and (2) fibroblasts and other cell types from local tissues. 23 The cell surface antigen CD151 has been previously characterized as a mesenchymal cell marker and is found on many different human cell types. 24, 25 Furthermore, CD45 is a human hematopoietic cell surface marker found on B and T cells, as well as on hematopoietic progenitors. 26 Tumors grown in XactMice contain a unique and quantifiable population of cells displaying both human cell surface antigens CD45 and CD151, which is absent in the nude and NSG mice. Likewise, cells removed from XactMice bone marrow, spleen and peripheral blood harbor similar double-positive populations, whereas cells from nude and NSG mice lack these human markers ( Figure 2 ). We observed that although the human cell population typically accounted for only 2-5% of the total bone marrow cells, this degree of engraftment was sufficient to produce immune cell infiltration into tumors and give rise to alpha smooth muscle actin+ cells.
To show that the CD45/CD151+ cells originate within the XactMice-humanized bone marrow we performed four different analyses using separate cohorts of XactMice. First, we used short tandem repeat analysis, a well-documented forensic examination that compares highly variable DNA loci by PCR to establish the relationship between two or more DNA samples. We purified DNA from CD45/CD151+ cells sorted from CUHN004 tumors grown on XactMice, and DNA from the originator CUHN004 patient sample (F0). We analyzed the DNA at two well-studied loci, TPOX and vWA, to identify short tandem repeat polymorphisms ( Figure 3a) . Our results show that the sorted cells are human and genetically distinct from tumor cells. 27 Further, CD151 immunofluorescence analysis revealed the presence of individual human cells scattered throughout the otherwise unstained tumor stroma in the XactMice. These stromal cells were not present in the NSG mice (Figures 3b and c) . Next, we performed fluorescent in situ hybridization (FISH) analysis, using species-specific probes for highly repetitive Cot-1 DNA to clearly identify the species of each cell. 28 We found that tumors in nude hosts were composed of human cells (red), encapsulated by and containing small islands of mouse stromal cells (green), as is typical of a xenograft tumor (Figure 3d) . 11 In contrast, tumors in the XactMice consisted of large bundles of human tumor cells (red), surrounded by bands of mouse stroma (green), in which human cells were interspersed ( Figure 3e ). Finally, we derived XactMice using HSPCs from female cord blood, and implanted tumors from a male patient. FISH analysis for X and Y chromosomes revealed tightly packed XY epithelial tumor cells surrounded by stromal cells of mouse origin in NSG mice (Figure 3f ), whereas in XactMice we observed individual XX cells scattered throughout the tumor stroma (Figure 3g ), in a pattern similar to that observed in the Cot-1 FISH analysis. Taken together, these analyses show that the engrafted HSPC progeny migrate from the XactMice bone marrow and are incorporated into implanted tumors.
The stroma of XactMice tumors is infiltrated with human T-and B-cell populations
To determine the types of human stromal cells infiltrating XactMice tumors, we stained tumor sections from the CUHN004 and CUHN013 F0 patient tumors and corresponding NSG and XactMice xenografts with either human or human plus mouse pan-leukocyte CD45 antibodies (Figures 4a and c) . Whereas the F0 tumors contained only human CD45+ cells (red) and the NSG tumors contained only mouse CD45+ cells (brown), the XactMice tumors contained both mouse and human CD45+ cells, indicating that HSPC-generated cells are invading these tumors. We performed dual staining with human-specific antibodies to CD45 and either CD3 (T cells), CD19 (B cells) or alpha smooth muscle actin (fibrocytes) (Figures 4d and f) . The human T-cell and B-cell populations identified were distributed in similar patterns throughout the F0 and XactMice tumors (generally less abundantly in XactMice), and were absent in NSG tumors from the same generation. The alpha smooth muscle actin staining was not human-specific, as can be seen in the NSG tumors, but CD45/alpha smooth muscle actin+ double-staining cells were identified in both the F0 and XactMice tumors, and they can be attributed to hematopoietic stem cells differentiation. We also stained for human CD4+ cells. Their presence in XactMice tumors indicates that the HSPC-generated T-cell progenitors can differentiate into T-helper cells (Figure 4g ).
Humanization reverses genetic drift after passage in immunecompromised hosts As the XactMice model is designed to support xenograft tumor growth in a native environment, it is critical to demonstrate that it reduces genetic drift from the originator tumor compared with conventional models. To this end, we micro-dissected CUHN004 and CUHN013 tumor cells from flash-frozen tumors passaged in nude, NSG and XactMice, as well as from the originator F0 patient tumors resected and flash-frozen at the time of surgery. We isolated RNA and performed next generation sequencing to compare gene expression between tumors. A summary of the sequencing data (Table 1) shows that the CUHN013 XactMice tumor transcriptome aligns more completely to the human genome than the nude or NSG-originated tumor transcriptomes. The tumor transcriptome from the CUHN004 XactMice aligns slightly less completely to the human genome than that from the corresponding nude mouse, but its alignment is more complete than that of the NSG mouse. Likewise, whereas a dendrogram of the CUHN013 shows that the XactMice and the F0 patient tumors are most similar, the dendrogram comparing RNA expression between the CUHN004 tumors indicates that the XactMice transcriptome clusters separately from all others, indicating a fundamental difference in its gene expression (Figure 5a ). It is possible that these differences arise as a consequence of their different prior passages in nude mice.
To determine the pattern of gene drift upon XactMice implantation, we systematically analyzed the CUHN004 and CUHN013 sequencing data to identify differentially expressed genes, whose expression is similar in the F0 patient and XactMice tumors but different from their expression in the nude and NSG tumors (Supplementary Table 1 ). Although the variability between the CUHN004 and CUHN013 tumors resulted in few overlapping genes, many of the genes identified were common to several general biological processes, including epithelial differentiation, peptidase inhibition, cell adhesion and protein processing (Supplementary Table 2 ). We captured all gene ontology (GO) terms associated with the differentially expressed genes and used them to perform a gene set enrichment analysis, calculating an enrichment score for each of these GO terms. Many of the most enriched GO terms are associated with the immune system, the extracellular matrix or epithelial-mesenchymal transition. We created heatmaps for both tumors, comparing the expression of several core genes linked to these GO terms (Figure 5b) , and we generated a waterfall graph depicting the relative enrichment of all GO terms, highlighting those relevant to the above-indicated pathways (Figure 5c ). In CUHN004, 13 of the top 20 most enriched GO terms are associated with the immune system, the extracellular matrix or epithelial-mesenchymal transition (P-value o 0.00001); for CUHN013, 15 of the top 20 fall within these categories (P-value o 0.00001) (Figure 5d ). Conversely, of the GO terms that are enriched in the nude and NSG tumors, few have a role in these processes.
To clarify the relationship between differentially expressed genes and the enriched processes identified by their GO terms, we identified many genes expressed exclusively in the F0 patient and Table 3 ). Many of these genes have a role in the immune response or in epithelial-mesenchymal transition, or are components of the extracellular matrix, indicative of the HSPC-derived invasive cells having an active role in stromal growth (Supplementary Table 4 ). In support of this, several of the differentially expressed genes are related to stromal processes. 29, 30 Humanization modulates lymphangiogenesis and cytokine expression Interestingly, our RNA sequencing data revealed increased expression of several pro-lymphangiogenic factors including vascular endothelial growth factor C and interleuin (IL)-8 in CUHN004; platelet-derived growth factor A and B, and endothelin-1 in CUHN013; and adrenomedullin, which was higher in both the CUHN004 and CUHN013 XactMice xenografts compared with those from the NSG controls (Figure 6a) . Given that the lymphatic vasculature has an essential role in immune surveillance, inflammation and tumorigenesis 31, 32 and that bone marrow derived cells contribute to lymphangiogenesis, 33 we assessed whether the expansion of the lymphatic vasculature occurs in the XactMice. We stained CUHN013 and CUHN004 tumors for lyve-1, a marker of lymphatic vasculature, 34 and observed increased intratumor lymphatic vessel density (lyve-1+ cells/mm 2 ) in XactMice tumors compared with tumors in NSG hosts (Figure 6b) .
XactMice tumors (Supplementary
Analysis of the RNA sequencing data also indicated that many cytokines and chemokines are among the differentially expressed A dashed line has been added to demarcate the approximate tumor-stroma boundary. In XactMice (g), the tumor cells are male, and the stroma is composed largely of mouse cells, but also contains female human cells. Expanded inserts were captured under increased magnification (×100). In all images, the scale bar equals 50 μm.
genes. To identify additional cytokines uniquely present in the XactMice, we profiled XactMice and NSG blood plasma on human cytokine arrays (Figure 6c and Supplementary Table 5 ). Although there is some antibody cross-reactivity between murine and human cytokines, we can still make several conclusions about the human cytokine signaling present in the XactMice. When no tumors were implanted, three cytokines were markedly elevated in the XactMice plasma: GM-CSF, CD54 and migration inhibitory factor. These cytokines are all known to modulate lymphoid or myeloid cell migration, and their elevated presence supports the role of functioning immune components in the XactMice. Conversely, four cytokines-C5/C5α, CD40l, IL-13 and CXCL12-were expressed more abundantly in the NSG plasma. This spurious binding prevents us from forming conclusions about possibly alterations in the XactMice plasma. However, even discounting these signals, the cytokine profiles of the NSG plasma from animals bearing either CUHN004 or CUHN013 tumors look quite similar to that observed from NSG mice without tumors, although IL-1rα and migration inhibitory factor are also highly expressed in the CUHN004 plasma (as predicted from RNA sequencing of this tumor). Conversely, increased concentrations of CD54, IL-1rα, IL-6, IL-8 and migration inhibitory factor are present in the plasma from XactMice bearing either CUHN004 or CUHN013 tumors. In addition, plasma from the CUHN004 XactMice contains increased levels of GM-CSF, chemokine (C-C motif) ligand 1, IL-13 and plasminogen activator inhibitor type 1, whereas that plasma from the CUHN013 XactMice lacks GM-CSF expression, implying a complex interplay between the signals generated by the HSPCs in the bone marrow and the tumors.
XactMice tumors present a dynamic microenvironment As patient tumor growth responds to sudden changes in the local environment, we examined the effects of 3Gy ionizing radiation to CUHN013 tumors on NSG and XactMice. An immunohistochemistry analysis of irradiated XactMice tumors reveals an influx of T cells, as would be expected from a functional immune system (Figure 6d) . 35 Lymph vessels, as visualized by lyve-1 staining, also rapidly expand and cluster with-and occasionally encompass-infiltrating immune cells, providing a potential avenue for their migration to and from the tumor stroma (Figure 6e) . Finally, expression of almost all cytokines falls sharply after irradiation, indicative of the marked changes produced by radiation within the tumor microenvironment (Figure 6c) . Only, three cytokines (CD40l, GM-CSF and IL-13) increased very modestly in the XactMice plasma. As CD40l and IL-13 expression were also found to be elevated in NSG mice without tumors, it is possible that the presence of some of these cytokines after irradiation indicates spurious cross-reactivity.
DISCUSSION
A tumor can be envisioned as the result of the growth and interaction of cancer cells with the surrounding fibroblast scaffolding, infiltrating immune cells and associated lymphatic vasculature. Without accounting for all of these components, a model system cannot hope to accurately recreate the conditions driving the original tumor's growth. We propose that the XactMice system represents an important step toward recapitulating a patient's tumor environment by creating an in vivo system in which a xenograft growth is at least partially regulated by a surrogate human immune system. Human blood cells originating in the engrafted bone marrow circulate throughout the tumor, altering cytokine expression, assisting in stromal deposition and increasing lymphangiogenesis throughout the tumor microenvironment. Their presence also alters gene expression within the tumor cells, regulating expression of genes critical in maintaining a tumor microenvironment. The observation that XactMice tumor implantation reversed the initial genetic drift observed after tumor passage in immune-compromised hosts indicates that this model enables tumors to revert to their original state.
We have also shown that the immune system engrafted into the XactMice is not only attendant but also capable of interacting with the grafted tumor. As tumors are constantly engaged with their surrounding and supportive stromal tissues, it is important that the XactMice model replicate this facet of cancer behavior. The immune system in XactMice responds rapidly and appropriately to an environmental insult within the tumor. Changes in immune cell infiltration, cytokine expression and lymphangiogenesis are fitting physiological responses to radiation and, again, are indicative of the value of the XactMice model. Also of importance is that this model is self-sustaining: the engrafted HSPCs can be purified from the bone marrow of the XactMice and re-engrafted into another generation of XactMice with HSPCs derived from the original donor source. Bird et al. 18 used the bone marrow cells obtained from an initial cohort of xenochimaeric NSG mice for serial transplantation studies. They transplanted 1 × 10 6 unfractionated bone marrow cells harvested from human HSPC xenochimaeric mice into a second cohort of irradiated NSG mice. The secondary cohort of xenotransplantrecipient mice were euthanized 12 weeks post transplant, and their bone marrow cells were assessed for the presence of human CD34+ cells by flow cytometry. They observed human CD45+/CD38+/CD34+ cells in the bone marrow of the secondary cohort of xenochimaeric NSG mice, documenting the feasibility of generating additional cohorts of xenochimaeric mice. Therefore, implanted patient xenografts could be continually propagated in an environment similar to that of the original tumor. As a first attempt to develop this model, the proof-of-concept studies presented in this report involved mice in which the human hematopoietic system and the tumor were derived from allogeneic sources. This allogeneic system did not significantly impact tumor growth. Future experiments will examine whether an allogeneic response could affect chemotherapy and radiotherapy in humanized mice. The long-term goal of these studies is to enable the generation of human xenochimaeric tumor bearing mice that harbor syngeneic tumor and hematopoietic cells. A syngeneic humanized mouse model could potentially recreate the patient tumor-immune microenvironment and serve as an invaluable platform in the investigation of the next generation of immunomodulatory chemotherapeutics.
Even though various types of humanized mice have been previously reported, they are typically produced by the injection of purified human CD34+ cells into sublethally irradiated mice 36 and have mainly been used to study the immune system, allograft rejection and blood cell differentiation. 37 Rongvaux recently described the generation of MITRG and MISTRG mice, which were engineered to express human cytokines that would support the development and function of monocytes, macrophages and NK RNA sequences generated from high-throughput sequencing were aligned to the human genome (NCBI 37.2). Resultant unaligned sequences were then aligned to the mouse genome (NCBI 37.2), and any remaining sequences were classified as unmatched, most likely owing to base repetition and/or sequencing errors.
XactMice-humanized PDX modelcells derived from the injection of human fetal liver cells. 17 As an analysis of the immune cell activity in these genetically engineered humanized mice, they implanted cell line-derived tumors and observed that human macrophages invaded these tumors in a VEGF-dependent manner. As presented, the Rongvaux model and the humanized mouse model previously described by Wege et al, After this enrichment analysis, GO terms were color-coded according to their overarching biological process, the most frequently observed of which were immune system (blue), extracellular matrix (ECM; pink) and epithelial-mesenchymal transition (EMT; green.) A paired z-test for proportions (inset table) shows that the enrichment of the GO terms representing each of these processes is statistically significant in genes differentially expressed in the F0 patient and XactMice tumors. do not attempt to recreate the microenvironment of a patient's tumor in a humanized mouse, but it nicely complements our observations concerning human immune cell invasion into cell line-derived tumors.
Cancer research has benefitted significantly from our ability to customize therapy in response to mutated genetic pathways that drive an individual's tumor growth. 39 The host's relevance in determining disease occurrence and outcome is now also increasingly evident and must be accounted for in developing tomorrow's therapies. 40 Stromal cells and immune cells are emerging as potent drivers of invasion and metastasis, and the XactMice model faithfully recreates the native tumor environment absent in current animal models. We predict that this model will be a useful tool in the rapidly expanding field of stroma-and/or immune-directed drug development.
MATERIALS AND METHODS
HSPC isolation and XactMice generation
Donated, de-identified cord blood was obtained from the University of Colorado cord blood bank (http://www.clinimmune.com/cordbloodbank/). HSPCs were expanded as previously reported.
18 NSG (Jackson Laboratories, Bar Harbor, ME, USA) mice were prepared as previously described. 18 After 8 weeks, mice were bled via the tail vein to assess HSPC engraftment. The peripheral blood was analyzed by flow cytometry, using human CD3, CD45 and/or CD151 (Biolegend, San Diego, CA, USA) antibodies. Tumor tissue and blood were collected in accordance with the protocol approved by the Colorado Multiple Institutional Review Board (COMIRB #08-0552 and #06-0720) and implanted on all mice as described. 19 Mouse irradiation CUHN013 xenograft-bearing mice were irradiated using an RS-2000 small animal irradiator (Rad Source Technologies, Suwanee, GA, USA), calibrated to deliver 1.15Gy X-ray radiation per minute. Mice were anesthetized via intraperitoneal injection with a ketamine (60 mg/kg)/xylazine (8 mg/kg) solution, then positioned beneath a lead/cadmium shield, designed to allow radiation to penetrate only the flank tumors. A 3Gy dose was administered to each tumor, and the mice were allowed to recover for 24 h before tissue collection.
Flow cytometry/cell sorting Excised tissues were prepared as previously described. 41 Cell suspensions were blocked by the addition of Gamunex (Baxter, Deerfield, IL, USA) for 30 min at room temperature, then washed in flow buffer (phosphatebuffered saline+2% fetal bovine serum) and incubated at room temperature for 1 h with the following antibodies (at a 1:10 final concentration): PerCP/Cy5.5-CD3, APC-CD34, PE-CD45 and/or APC-CD151 (BioLegend). Flow analysis was conducted on a Beckman Coulter Cyan. Cell sorting was performed on the Beckman Coulter Moflo XDP 70. Data analysis was performed using Summit, V5.1 (Beckman Coulter, Brea, CA, USA).
Short tandem repeat PCR analysis
Genomic DNA from tumor tissue was isolated using a QIAamp DNA Mini Kit (Qiagen, Germantown, MD, USA). Short tandem repeat amplification was performed using Taq polymerase (Promega, Madison, WI, USA) on a GenAmp 9700 machine (Applied Biosystems, Grand Island, NY, USA) with the following primers (5′-3′): TPOX-For ACTGGCACAGAACAGGCACTTAGG, TPOX-Rev GGAGGAACTGGGAACCCCACAGGTTA, vWA-For GGACAGATGA TAAATACATAGGATGGATGG and vWA-Rev GCCCTAGTGGATGATAAGAAT AATCAGTATGTG. The resultant DNA was visualized using an Agilent Bioanalyzer 2100 with a DNA-1000 chip (Agilent, Santa Clara, CA, USA).
Immunofluorescence
Slides were de-paraffinized in xylene twice for 5 min and rehydrated in graded concentrations of ethanol. They were washed 3 × in phosphatebuffered saline and blocked with 15% goat serum in mouse IgG before the addition of CD151 (Novus Biologicals, Littleton, CO, USA) at a 1:50 concentration. Alexa Fluor goat-α-rabbit 488 (Invitrogen, Grand Island, NY, USA) was added for secondary staining, and the slides were incubated for 1 h at room temperature, washed 3 × in phosphate-buffered saline and covered with Fluoromount-G (SouthernBiotech, Birmingham, AL, USA).
Histology/immunohistochemistry
For single staining with the human CD45 antibody (Dako, Carpinteria, CA, USA) or mouse lyve-1 (Abcam, San Fransisco, CA, USA), the samples were incubated with antibody, then rinsed and a secondary reagent, APconjugated MACH2 Mouse Polymer (BioCare Medical, Concord, CA, USA), room temperature for CD45 staining or EnVision+Dual Link-HRP Polymer (Dako) for lyve-1 staining was applied before development with Vulcan Fast Red Chromogen (BioCare Medical) or DAB+ (Dako). For dual staining of mouse and human CD45, anti-mouse CD45 antibody (BD Pharmingen, San Jose, CA, USA) was applied, followed by a secondary rabbit anti-rat biotinylated antibody (Dako) and streptavidin-HPR conjugated solution (Dako). The CD3, lyve-1 (Abcam) and CD19 (MyBiosource, San Diego, CA) antibodies were applied at the appropriate dilution, followed by HRPconjugated EnVision+Dual Link System (Dako). In all cases, primary staining was developed using DAB+ chromogen solution (Dako).
FISH analysis
The sections were subjected to a dual-color FISH assay using Vysis CEPX SpectrumOrange/Y SpectrumGreen probe (Abbott Molecular, Abbott Park, IL, USA) following standard laboratory protocol. After post-hybridization washes, the slides were dehydrated in ethanol, and the chromatin was counterstained with 4',6-diamidino-2-phenylindole (0.3μg/ml in Vectashield mounting medium, Vector Laboratories, Burlingame, CA, USA).
Cytokine arrays
Human cytokine arrays (Panel A, R&D Systems, Minneapolis, MN, USA) were processed according to the manufacturer's instructions, using 150 µl of the indicated NSG or XactMice plasma (from blood collected in 50 U/ml heparin and centrifuged 10 min at 1800 rcf to remove platelets). Digital copies of the developed film were quantified using ImageJ software.
Laser-capture microscopy Eight micron frozen sections of tissue were cut using a cryostat, dehydrated through graded solutions of alcohols and xylene, and airdried for 5 min before being put into an Arcturus XT Laser Capture Microdissection Instrument (Applied Biosystems).
RNA extraction
Tissue was placed in 300 μl of QIAzol and homogenized using the MP Biomedicals (Santa Ana, CA, USA) Fast Prep 24. RNA was extracted from laser capture microdissection-captured cells and tissue using the RNeasy Mini RNA purification protocol (Qiagen). Total RNA was quantified on a Nanodrop 1000 (Thermo Scientific, Waltham, MA, USA).
RNA sequencing
Libraries were constructed using 1 μg total RNA, following the Illumina TruSeq RNA Sample Preparation v2 Guide. The products were amplified by PCR to create a complementary DNA library, which was then validated on the Agilent 2100 Bioanalyzer using DNA-1000 chip. Cluster generation was performed on the Illumina cBot, using a Single Read Flow Cell with a Single Read cBot reagent plate (TruSeq SR Cluster Kit). Sequencing of the clustered flow cell was performed on the Illumina HiSeq 2000, using TruSeq SBS v3 reagents (Illumina, San Diego, CA, USA).
Bioinformatics
The RNA reads were mapped against the human genome using Tophat (version 2.0.5), 42 using the NCBI reference annotation as a guide. Cufflinks (version 2.0.2) 43 was used to assemble the transcripts. Differentially expressed genes between F0/XactMice and the NSG/Nude were identified using CuffDiff and a fold-change threshold of at least two. Top pathways/ gene ontologies were identified using DAVID. 44, 45 Gene set enrichment analysis (v. 2.07) was conducted on the collapsed data using the Kyoto Encyclopedia of Genes and Genomes and GO pathway definitions obtained from the Molecular Signatures Database, v.3.1. Pathways with a nominal P-value ⩽ 0.05 were deemed significant. All analyses except gene set enrichment analysis were conducted in R/Bioconductor, v. 3.0.1.
